# Sapu003 in Advanced mTOR-sensitive Solid Tumors

Source: https://onco.cc/trials/nct07369505/  
OnCo record `nct07369505` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Sapu003 (SAPU-003, everolimus Deciparticle) run by SAPU NANO (US) LLC, now recruiting.

## Summary

Sapu003 in Advanced mTOR-sensitive Solid Tumors is a phase 1 interventional study registered as NCT07369505 by SAPU NANO (US) LLC, with 27 participants planned, started 2025-12-15. Conditions recorded: Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC) and Hepatocellular Carcinoma (HCC). Interventions recorded: Sapu003 and Exemestane 25 MG.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07369505
- Phase: 1
- Setting: A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)
- Sponsor: SAPU NANO (US) LLC
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT07369505: https://clinicaltrials.gov/study/NCT07369505

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Sapu003 (SAPU-003, everolimus Deciparticle)](https://onco.cc/drugs/sapu-003/)
- companies: [Sapu Nano](https://onco.cc/companies/sapu-nano/)

---
JSON: https://onco.cc/api/v1/entities/nct07369505.json